Amalgamated Bank Biomarin Pharmaceutical Inc Transaction History

Amalgamated Bank

  • $12.2 Billion
  • Q4 2024

A detailed history of Amalgamated Bank transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Amalgamated Bank holds 91,048 shares of BMRN stock, worth $6.32 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
91,048
Previous 90,666 0.42%
Holding current value
$6.32 Million
Previous $6.37 Million 6.09%
% of portfolio
0.05%
Previous 0.05%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025
BUY
$61.93 - $70.49 $23,657 - $26,927
382 Added 0.42%
91,048 $5.99 Million
Q3 2024

Oct 30, 2024
SELL
$69.02 - $93.84 $362,769 - $493,223
-5,256 Reduced 5.48%
90,666 $6.37 Million
Q2 2024

Aug 12, 2024
BUY
$74.43 - $92.22 $6.34 Million - $7.86 Million
85,177 Added 792.71%
95,922 $7.9 Million
Q1 2024

Apr 23, 2024
SELL
$83.81 - $99.0 $470,928 - $556,281
-5,619 Reduced 34.34%
10,745 $938,000
Q4 2023

Feb 06, 2024
SELL
$76.22 - $98.51 $327,974 - $423,888
-4,303 Reduced 20.82%
16,364 $1.58 Million
Q3 2023

Nov 08, 2023
BUY
$85.07 - $94.48 $207,485 - $230,436
2,439 Added 13.38%
20,667 $1.83 Million
Q2 2023

Aug 11, 2023
SELL
$86.68 - $100.3 $26,177 - $30,290
-302 Reduced 1.63%
18,228 $1.58 Million
Q1 2023

May 02, 2023
BUY
$87.74 - $117.27 $7,984 - $10,671
91 Added 0.49%
18,530 $1.8 Million
Q4 2022

Feb 10, 2023
BUY
$80.93 - $108.63 $9,954 - $13,361
123 Added 0.67%
18,439 $1.91 Million
Q3 2022

Nov 09, 2022
SELL
$82.16 - $96.94 $98,345 - $116,037
-1,197 Reduced 6.13%
18,316 $1.55 Million
Q2 2022

Aug 15, 2022
BUY
$71.48 - $86.85 $107,005 - $130,014
1,497 Added 8.31%
19,513 $1.62 Million
Q1 2022

Jun 30, 2022
SELL
$74.28 - $92.69 $81,485 - $101,680
-1,097 Reduced 5.74%
18,016 $1.39 Million
Q4 2021

Feb 15, 2022
SELL
$71.72 - $91.47 $13,698 - $17,470
-191 Reduced 0.99%
19,113 $1.69 Million
Q3 2021

Oct 29, 2021
SELL
$74.77 - $85.47 $130,922 - $149,657
-1,751 Reduced 8.32%
19,304 $1.49 Million
Q2 2021

Aug 16, 2021
BUY
$75.51 - $84.79 $924,544 - $1.04 Million
12,244 Added 138.96%
21,055 $1.76 Million
Q1 2021

May 13, 2021
SELL
$74.73 - $90.69 $35,571 - $43,168
-476 Reduced 5.13%
8,811 $665,000
Q4 2020

Feb 12, 2021
SELL
$72.61 - $90.2 $9,874 - $12,267
-136 Reduced 1.44%
9,287 $814,000
Q3 2020

Oct 30, 2020
SELL
$71.87 - $131.03 $10,996 - $20,047
-153 Reduced 1.6%
9,423 $717,000
Q2 2020

Aug 10, 2020
SELL
$79.55 - $124.22 $1.43 Million - $2.23 Million
-17,977 Reduced 65.25%
9,576 $1.18 Million
Q1 2020

May 13, 2020
SELL
$71.37 - $96.85 $68,800 - $93,363
-964 Reduced 3.38%
27,553 $2.33 Million
Q4 2019

Feb 13, 2020
BUY
$64.27 - $86.37 $85,993 - $115,563
1,338 Added 4.92%
28,517 $2.41 Million
Q3 2019

Nov 13, 2019
BUY
$67.4 - $85.11 $395,503 - $499,425
5,868 Added 27.54%
27,179 $1.83 Million
Q2 2019

Aug 14, 2019
SELL
$80.35 - $93.9 $227,952 - $266,394
-2,837 Reduced 11.75%
21,311 $1.83 Million
Q1 2019

May 15, 2019
BUY
$84.2 - $98.62 $59,950 - $70,217
712 Added 3.04%
24,148 $2.15 Million
Q4 2018

Feb 15, 2019
SELL
$80.14 - $106.07 $60,425 - $79,976
-754 Reduced 3.12%
23,436 $2 Million
Q3 2018

Nov 14, 2018
SELL
$93.92 - $105.72 $53,440 - $60,154
-569 Reduced 2.3%
24,190 $2.35 Million
Q2 2018

Jul 18, 2018
BUY
$76.01 - $99.03 $148,523 - $193,504
1,954 Added 8.57%
24,759 $2.33 Million
Q1 2018

May 22, 2018
BUY
$77.67 - $92.63 $194,874 - $232,408
2,509 Added 12.36%
22,805 $1.85 Million
Q4 2017

Feb 13, 2018
BUY
$80.76 - $95.13 $165,719 - $195,206
2,052 Added 11.25%
20,296 $1.81 Million
Q3 2017

Nov 09, 2017
BUY
$80.6 - $94.95 $1.47 Million - $1.73 Million
18,244
18,244 $1.7 Million

Others Institutions Holding BMRN

# of Institutions
628
Shares Held
183M
Call Options Held
2M
Put Options Held
1.67M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.9B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email